Geneva, Switzerland, and São Paulo, Brazil – May 15, 2008 – Geneva Bioinformatics (GeneBio) SA and GE Healthcare Life Sciences Latin America (GEHC-LS) today announced a distribution agreement whereby GEHC-LS will distribute GeneBio’s Phenyx MS identification platform throughout Latin America. This deal builds upon the long lasting relationship between GE Healthcare and GeneBio concerning the distribution of GeneBio’s Melanie imaging platform.
Under the terms of the agreement, GEHC-LS will distribute Phenyx within the Latin American market as the exclusive MS software component of their impressive product offerings. The deal encompasses GeneBio’s Phenyx (for MS-MS identification), Aldente (for PMF analysis) as well as Phenyx’s Daemon and other MS related software products that GeneBio will be putting on the market in the future.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment while offering a flexible user experience and an adaptable architecture to help instil confidence in results assessment. (http://phenyx.vital-it.ch/pwi)
“We fully believe in bringing quality products and companies to our distribution network,” said Gyvair Molinari, Business Director of GE Healthcare Life Sciences. “We have partnered with GeneBio for many years over Melanie and ImageMaster. We know and trust GeneBio’s team, both the quality of the products they develop and the scientific knowledge they possess. Their high level of expertise and extensive client support lead us to believe that the Phenyx platform will have an immediate impact on an expanded GEHC-LS offering in Latin America. We look forward to continuing our relationship with GeneBio and to the success of Phenyx in the Latin American markets.”
“This is a great step forward for Phenyx and GeneBio; we are very excited about what this distribution deal will bring,” said Nasri Nahas, CEO of GeneBio. “GE Healthcare’s reputation and distribution network are both first-class; this deal allows us to take advantage of these factors and bring Phenyx to the fast growing Latin American market in a very efficient manner. GeneBio has been working with GEHC-LS since 2004 on Melanie’s distribution and we have experienced a very professional and dynamic team that stays in close contact with its clients and always endeavors to bring them the best for their research. We look forward to continuing our long-term relationship with GEHC-LS and to the successful expansion of our Phenyx business in Latin America.”
For more information concerning this distribution deal and for Phenyx product demonstrations, please visit GeneBio booth #27 at the upcoming ASMS Conference on Mass Spectrometry in Denver, Colorado, from June 1-5.
About GE Healthcare Life Sciences
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest. GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Geneva Bioinformatics (GeneBio) SA is a leading bioinformatics company providing the life science community with world-class proteomics software that bridges the gap between information gathering and knowledge generation. Established in 1997, we focus our expertise on protein identification and characterization as well as proteome imaging, offering clients and partners a high degree of specialization essential to proteomics research. Close ties to academic peers and a thorough network of distribution and strategic partners give us both unfettered access to scientific excellence and recognized market presence so that we may best serve the scientific community. For more information about GeneBio, please visit: www.genebio.com.